Nonadherence with angiotensin-converting enzyme inhibitor therapy: A comparison of different ways of measuring it in patients with chronic heart failure

Journal of the American College of Cardiology

Volumn 34, Issue 7, 1999, Pages 2072-2077

  Struthers, Allan D ^a   MacFadyen, Robert ^a   Fraser, Callum ^a   Robson, Jess ^a   Morton, James J ^c   Junot, Christophe ^b   Ezan, Eric ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b DIF   (France)

^c WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; LISINOPRIL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME INHIBITION; HEART FAILURE; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME;

AGED; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; CHRONIC DISEASE; DIURETICS; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; FUROSEMIDE; HEART FAILURE, CONGESTIVE; HUMANS; LISINOPRIL; OLIGOPEPTIDES; PEPTIDYL-DIPEPTIDASE A; RADIONUCLIDE VENTRICULOGRAPHY; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 0033430350     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00439-8     Document Type: Article

References (19)

1. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
2. Ghali J.K., Kadakis S., Cooper R., Ferlinz J. Precipitating factors leading to decompensation of heart failure. Arch Intern Med. 148:1988;2013-2016.
3. Monane M., Bohn R.L., Gurwitz J.H., Avorn J. Noncompliance with congestive heart failure therapy in the elderly. Arch Intern Med. 154:1994;433-437.
4. Rich M.W., Beckham V., Wittenberg C. A multidisciplinary intervention to prevent the readmission of elderly patients with CHF. N Engl J Med. 333:1995;1190-1195.
5. Haynes R.B., McKibbon K.A., Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet. 348:1996;383-386.
6. MacFadyen R.J., Struthers A.D. Practical assessment of compliance with ACE inhibitor therapy - a novel approach. J Card Pharm. 29:1997;119-124.
7. Struthers AD, Anderson G, MacFadyen RJ, et al. Nonadherence with ACEI treatment is common in heart failure and can be detected by routine serum ACE Activity assays. Heart. In Press.
8. Azizi M., Ezan E., Nicolet L., et al. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline a new marker of chronic ACE inhibition . Hypertension. 30:1997;1015-1019.
9. Nussberger J., Brunner D., Keller I., Brunner H.R. Measurement of converting enzyme activity by antibody tapping of generated angiotensin II comparison with two other methods . Am J Hypertens. 5:1992;393-398.
10. Pflugfelder P.W., Baird M.G., Tonken M.J., et al. Clinical consequences of ACEI withdrawal in CHF a double blind, placebo controlled study of quinapril . J Am Coll Cardiol. 22:1993;1557-1563.
11. Morton J.J., Webb D.J. The measurement of angiotensin II. Clin Sci. 68:1985;483-484.
12. Pradelles P., Frobert Y., Creminon C., et al. Negative regulator of pluripotent haematopoietic stem cell proliferation in human white blood cells and plasma as analysed by enzyme immunoassay. Biochem Biophys Res Commun. 170:1990;986-993.
13. Ezan E., Carde P., Le Kerneau J., et al. Pharmacokinetics in healthy volunteers and patients of AcSDKP (serasperide), a negative regulator of haematopoiesis. Drug Metab Dispos. 22:1994;843-848.
14. Corlett A.J. Aids to compliance with medication. BMJ. 313:1996;926-929.
15. Swedberg K., Eneroth P., Kjekshus J., et al. Hormones regulating cardiovascular function in patients with severe CHF and their relation to mortality. Circulation. 82:1990;1730-1735.
16. Azizi M, Ezan E, Reny JL, et al. Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during ACE inhibition in humans. Hypertension. In Press.
17. Biollaz J., Schelling J.L., Jacot-Des-Combes B., et al. Enalapril maleate and a lysine analogue (MK521) in normal volunteers relationship between plasma drug levels and the renin angiotensin system . Br J Clin Pharmacol. 14:1982;363-368.
18. van Veldhuisen D.J., Genth-Zotz S., Braouwer J., et al. High dose versus low dose ACE inhibition in CHF. J Am Coll Cardiol. 32:1998;1811-1818.
19. Davidson N.C., Coutie W.J., Webb D.J., Struthers A.D. Hormonal and renal differences between low dose and high dose ACEI treatment in patients with chronic heart failure. Heart. 75:1996;576-581.